3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbonitrile | 1435945-94-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbonitrile
• CAS: 1435945-94-0
• 化学式: C₁₇H₁₇BrN₆O
• 分子量: 401.266
• InChiKey: LDDNMPXBMPKSIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.35
• 重原子数：
  25.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  78.17
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbonitrile 在 xantphos 、 盐酸羟胺 、 sodium carbonate 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 4-[[2-[8-(5-Propan-2-yl-1,2,4-oxadiazol-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl]pyrimidin-5-yl]oxymethyl]pyridine-3-carbonitrile
  参考文献：
  名称：

  Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human

  摘要：

  A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.006
• 作为产物：
  描述：

  tert-butyl 3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate 在 盐酸 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbonitrile
  参考文献：
  名称：

  Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human

  摘要：

  A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.006